Revel Pharmaceuticals and Collaborators Report Enzymatic Reversal of a Chemical Hallmark of Aging in Human Tissue
Study published in Nature Communications describes CMLase, an engineered enzyme that reverses a form of protein damage long considered permanent
Shows that structural damage in human tissue can potentially be reversed
Revel Pharmaceuticals today announced a study published by its scientists as well as researchers at Calico and the University of Colorado Anschutz Medical Campus, in Nature Communications. The paper describes CMLase, an engineered enzyme that reverses a stable form of chemical damage that builds up in long-lived proteins over decades.
The damage, known as Nε-carboxymethyl-lysine (CML), is a type of advanced glycation end product ("AGE"). It forms when sugars react with proteins in a process similar to the browning reaction that turns bread into toast. In the body this reaction unfolds slowly over a lifetime, altering proteins in skin, blood vessels, and other tissues.
